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Implication for health policy/practice/research/medical education:
Dextranomer/hyaluronic acid subureteric injection provides acceptable resolution rate among vesicoureteral reflux (VUR) 
patients and this highlights the necessity for the strict implementation of it in VUR.
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Introduction: Dextranomer/hyaluronic (Dx/HA) acid is the only tissue-augmenting agent 
approved by the Food and Drug Administration (FDA) for the vesicoureteral reflux (VUR) 
treatment. 
Objectives: We aimed to evaluate short-term outcomes of the Dx/HA in patients who had 
undergone subureteric injection.
Patients and Methods: In this study, 30 patients with VUR diagnosis who had indications 
for open surgery were enrolled in the study. Patients underwent subureteric Dx/HA injection. 
Additionally patients underwent a one-year follow up period, subsequently. Follow up 
included urine analysis, urine cultures and kidney and urinary tract ultrasonography study.
Results: Of a total 30 patients, 8 patients (27%) were male and 22 patients (73%) were female. 
The mean age of patients was 25.19 ± 0.70 months. Postoperative VUR resolution was observed 
in 28 patients (93.3%). Moreover, during one year follow up, urinary tract infection (UTI) was 
not reported in patients. However, recurrent VUR was detected in 8 patients (27%) during 
ultrasonography follow up. Analysis showed no significant difference of recurrence in VUR 
between males and females (P = 0.285) and VUR severity (P = 0.1). There was a significant 
relationship between recurrent UTI history before intervention and VUR recurrence after 
subureteric injection (P = 0.007).
Conclusion: Dx/HA acid subureteric injection provides acceptable resolution rate among 
VUR patients, but its biodegradability causes VUR recurrence during one-year follow up.
A R T I C L E  I N F O
Keywords:
Vesicoureteral reflux
Dextranomer
Subureteric injection
Urinary tract infection
Article History:
Received: 20 October 2017 
Accepted: 4 February 2018 
Published online: 19 February 2018
 
Article Type:
Original
A B S T R A C T
O
rig
in
al
Introduction
Vesicoureteral reflux (VUR) is a common problem in 
children, which increases the risk of the urinary tract 
infection (UTI), nephropathies and end-stage renal 
diseases. VUR is characterized by backflow of the urine 
from bladder toward the kidney, which affects 1%-3% of 
all children (1,2). While VUR pathophysiology leads to 
spontaneous resolution during first five years in most of 
the cases, some serious complications include recurrent 
UTI, renal injury and chronic kidney diseases (3-5). Three 
main therapy methods have been introduced for VUR 
treatment including observational therapy, prophylactic 
antibiotic administration, ureteroneocystostomy and 
endoscopic subureteral injection (1,6,7). Observational 
therapy emphasizes the spontaneous resolution of the 
VUR, however several studies showed incidence rate of 
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approximately 15% in all children (8). In addition, some 
reports showed that prophylactic antibiotic not only 
cannot prevent pyelonephritis but also leads to UTI with 
antibiotic resistant organisms that make more challenging 
problems (9-11). 
In 1981, Matouschek, firstly described the endoscopic 
subureteral injection for VUR treatment (12). Since 1984, 
O’Donnell and Puri popularized endoscopic sub-ureteral 
transurethral injection (STING) modality for VUR 
treatment. It has become one of the most attractive and 
first line therapy for children with VUR due to its high 
success rate, minimum aggression and few complications 
(13-16). Although, open surgery is still considered as 
gold standard for VUR treatment, however, STING has 
several advantages including simplicity, safety, quickness 
with low aggression which can provide an alternative 
treatment for open surgery (17,18). Since three decades 
ago, dextranomer/hyaluronic acid copolymer (Dx/HA) 
(Deflux) was the first tissue augmenting substance that was 
approved by the Food and Drug Administration to be used 
in VUR (19,20). Additionally, Dx/HA is a biocompatible, 
synthetic and non-immunogenic agent. Its biochemical 
characteristics make it susceptible to biodegradability 
(21). However, several studies reported the high rate of 
VUR recurrence in patients who had undergone STING 
by Dx/HA at long-term follow up, especially in patients 
suffering from high-grade VUR (22). 
Objectives
This study was aimed to evaluate the Dx/HA (Deflux) 
efficacy and short-term complications in VUR patients 
who had undergone STING.
Patients and Methods
Target population
From February 2015 to March 2017, a prospective 
study was carried out in a single center in Urmia, West 
Azerbaijan, Iran. During this period, due to lack of the 
resources and follow up possibility, 30 children with age 
range of 7 months to 15 years old were enrolled in the study 
using convenience sampling. Before intervention, patients 
underwent kidneys and urinary tract ultrasonography 
study in order to evaluate hydronephrosis following VUR. 
Then patients underwent modified STING using rigid 
cystoscopy and 3.7 FR catheter to inject settled amount 
of the Dx/HA (Deflux). The amount of injected drug was 
recorded for each patient. The length of stay in hospitals 
and preoperative complications were recorded for all 
patients. Further, kidney and urinary tract ultrasonography 
were conducted during the first and third month after 
intervention as postoperative follow up. In addition, 
patients underwent voiding cystourethrogram (VCUG) to 
evaluate VUR during third month postoperative. Finally, 
one year after the intervention, patients had undergone 
last follow up session to evaluate STING success rate and 
postoperative complications.
Inclusion criteria were included as follows: 1. Children 
aged 1 to 5 years old with bilateral grade III-IV VUR 
without resolution during follow up, 2. Children aged 
6-10 years old with unilateral grade III-IV VUR without 
resolution during observational therapy, 3. Children 6-10 
years old with bilateral grade III-IV VUR, 4. Children aged 
1-5 years old with unilateral or bilateral grade IV VUR that 
did not resolve during follow up, 5. Children aged 6-10 
years old with grade IV VUR and 6. Children older than 
one year old with a renal injury during imaging. Exclusion 
criteria were included patients who had a previous history 
of anti-reflux surgery and secondary reflux.
Ethical issues 
The research followed the tenets of the Declaration 
of Helsinki. All process of the study and probable 
complication were described for the parents before any 
intervention and all parents gave their written informed 
consent. This study was approved by the ethics committee 
of Urmia University of Medical Science and the objectives 
of the study were explained to all parents of participants 
and all of them accepted to participate and were assured of 
the confidentiality of information as well as the voluntary 
nature of participating in the study. 
Statistical analysis 
All data were analyzed using SPSS software version 18 and 
descriptive statistics and independent t test were used. 
Dependent variables were described as mean ± standard 
deviation (SD) and independent variables were expressed 
as frequency and percentages. Chi-square, independent t 
tests and ANOVA were used to determine the relationship 
between independent and dependent variables. The level 
of significance was considered less than 0.05.
Results
In the current study, during one-year period, 30 patients 
with VUR diagnosis who had indications for open surgery 
were enrolled. Of 30 patients, 8 patients (27%) were male 
and 22 patients (73%) were female with the mean age of 
the 25.19 ± 0.70 months (range; 7 to 93 months). Positive 
family history for VUR was recorded in two patients. 
Regarding the physical examination, the most prevalent 
complaint was pain and crying (53%). Dysuria and 
hematuria were the other common symptoms. Eighteen 
patients (60%) had unilateral VUR, while 12 patients 
(40%) suffered bilateral VUR. Left kidneys (60%) were 
the most common refluxing renal unit (RRU) suffering 
VUR. Twenty-six patients (86%) had a positive history of 
the previous UTI, however, despite prophylactic antibiotic 
therapy, UTI was detected in 24 patients (80%) (Table 1).
During preoperative and postoperative di-mercapto 
succinic acid (DMSA) scan study for evaluating renal 
dysfunctions following VUR, renal injury was detected 
in 26 (86.7%) and 14 patients (46%), respectively. 
Postoperatively, 28 patients (93.3%) had successful Dx/HA 
STING. However, regarding postoperative complications, 
postoperative vesicoureteral junction obstruction (VUJO) 
following Dx/HA STING was detected in 4 patients 
(13.3%). The mean amount of the injected tissue-
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augmenting agent was 0.73 ± 0.50 mm. Accordingly, 
postoperative urinary tract ultrasonography approved 
effective injection in all patients. The mean length of stay 
in hospital was 1.2 ± 0.4 days.
During follow up period, there was no report of the 
VUR recurrence or any other complication in first and 
third months. However, after one year, recurrent VUR 
was reported in 12 patients (42.8%) that detected during 
ultrasonography follow up in all patients.
The chi-square test showed no significant difference 
between female and male regarding the VUR recurrence 
(P = 0.285). Considering the type of the VUR among 
patients with recurrent VUR, 5 patients had bilateral VUR 
before STING and 7 patients had suffered from unilateral 
VUR. In this study no significant difference was seen 
in VUR recurrence between the groups (P = 0.12) (chi-
square test). During one-year follow up, six patients (50%) 
had right RRU. Similarly, six patients (50%) had left RRU, 
while analysis by chi-square test showed no significant 
correlation between the sides of the involvement with 
VUR recurrence (P = 0.438).
Eight patients (33.3%) with failed prophylactic antibiotic 
therapy experienced recurrent VUR one year after 
intervention, however, 4 patients with VUR recurrence 
did not have the failed antibiotic therapy history 
before intervention. Likewise, chi-square test showed a 
significant difference between the groups with a positive 
and negative history of the failed prophylactic antibiotic 
therapy regarding VUR recurrence (P = 0.007).
Discussion
In the present study, the results showed high success rate 
(93.3%) for Dx/HA subureteral injection in VUR treatment 
during one-year follow up. In our study, 12 patients (42.8%) 
had recurrent VUR during ultrasonography follow up. 
We found no significant correlation between the patients’ 
gender and RRU involvement with STING success rate. 
However, there was a significant relationship between 
recurrent UTI history and STING failure. Nonetheless, it 
can be estimated that history of the recurrent UTI before 
intervention may lead to higher probability of the STING 
failure in pediatrics.
Since three decades ago endoscopic sub-ureteric injection 
for VUR treatment was described for the first time. It has 
been a competitive alternative for open surgery, due to 
its acceptable success rate, safety and simplicity, less time 
consuming and short length of stay in hospital (12,20). 
Although the success rate for endoscopic interventions 
in VUR treatment varies between 70% and 90% in the 
literature, the optimal technique and bulking agent for 
STING are controversial (23,24). In addition, it is believed 
that the advantages of endoscopic intervention provide 
a possibility to repeat the procedure in case of failure or 
recurrence (25). For the first time, Matouschek used Teflon 
particles for injection (12). Stenberg and Lackgern were 
first persons to introduce Dx/HA as a bulking agent and 
tissue-augmenting agent to sub-ureteric injection using 
STING procedure and they reported cure rate of 68% 
during 3-month follow up (26). However, further reports 
using modified STING procedure had high cure rate (90%). 
The results were significant only in patients with grad III 
VUR. Among several bulking agents used for STING 
procedure in VUR treatment such as silicone, autogenous 
blood, chondrocytes and polydimethylsiloxane, Dx/HA 
acid was the only agent approved by the FDA for VUR 
treatment during STING procedure (19). According to 
previous studies, Dx/HA acid is a non-immunogenic 
material, which has no potential carcinogenic effects. 
Moreover, it has been reported to be durable, but some 
studies suggested that its biodegradability leads to lower 
durability and VUR recurrence following degradation 
(27,28). Although many studies suggest that appropriate 
selection of patients can lead to higher success rate, lower 
recurrence and complications, however biodegradable 
agents such as Dx/HA may cause VUR recurrence and 
failure during long-term follow up (25).
The reported success rate is 70% for VUR correction using 
STING procedure in the literature (8,23). In the current 
study, the success rate for endoscopic correction of the 
VUR using Dx/HA injection was 93.3%, which provides 
a higher rate compared to the literature. However, in a 
study by Wadie et al, the overall success rate was reported 
77.4% during single Dx/HA injection (8). Several studies 
evaluated poly-acrylate polyalcohol copolymer (PPC) as 
an effective and safe material in VUR correction instead 
of Dx/HA and its success rate has been reported more 
than 90% (28,29). Therefore, it should be highlighted 
that appropriate selection of the patients to undergo 
endoscopic correction of the VUR, not only enhances 
procedure success rate, but also may provide better 
symptoms resolution. 
Various preoperative factors including younger age before 
treatment and previous history of the failed endoscopic 
injection may be related to the intervention failure, which 
was detected by Serkan et al (25). On the other hand, 
some other studies suggested that preoperative history 
of dysfunctions and neurogenic disorders have a role in 
the failure of VUR endoscopic treatment (30-32). We 
found patients with the previous history of recurrent UTI 
significantly had the high rate of treatment failure. This 
Table 1. Patients’ data
Variable No. %
Type of VUR
Unilateral 18 60
Bilateral 12 40
Gender
Boy 8 27
Girl 22 73
Kidney
Right 18 60
Left 12 40
History of UTI
Yes 28 86
No 2 14
Renal Injury detected by DMSA
Preoperative 26 86.7
Postoperative 14 46
Abbreviations: VUR, vesicoureteral reflux; UTI, urinary tract infection; 
DMSA, Dimercaptosuccinic acid.
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finding demonstrates the role of recurrent UTI before 
intervention as an unfavorable risk for results. 
In previous studies, the incidence of the UTI after open 
surgery of VUR is approximately 10%. In the study of 
Lackgern et al, the incidence of the UTI in VUR patients 
who had recurrent VUR following endoscopic subureteric 
injection of the Deflux reduced to 8%, comparable to 
the study by Wadie et al. They detected 13% recurrent 
infection after endoscopic intervention in patients (8,33). 
However, in our study, none of the patients developed UTI 
after Dx/HA sub-ureteric injection during one-year follow 
up. On the other hand, VUR recurrence detected in none 
of the patients during ultrasonography studies at the end 
of the follow up. Therefore, our results showed recurrent 
UTI’s eradication in 100% of the patients. Despite 
previous studies that evaluated Dx/HA sub-ureteric 
injection, none of the patients developed any significant 
signs or symptoms related to procedure complications in 
the present study. 
Conclusion
Dx/HA acid is a non-immunogenic and safe material 
for sub-ureteral injection treatment of the VUR and 
provides acceptable resolution rate among patients, but 
its biodegradability causes VUR recurrence after one-year 
follow up, which leads to needing for the second injection 
in the future.
Limitations of our study
Our study had some limitations including; 1; inability to 
perform long-term follow up, 2; enrolling few patients 
to the study and 3; not evaluating the effect of injection 
amount on the results of the intervention. The small 
sample size of studies conducted in this field was the 
potential limitation of this study. There is still need to 
further studies to access additional information about this 
issue. 
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